The Bleeding With Antithrombotic Therapy Study 2

Conditions

Cerebrovascular and Cardiovascular Diseases

Brief summary

The purpose of this study is to determine the incidence and severity of bleeding complications in patients with cerebrovascular and cardiovascular diseases treated with oral antithrombotic therapy.

Yoshimura S, Miwa K, Koga M, Tanaka K, Yagita Y, Nagakane Y, Hoshino H, Terasaki T, Shiozawa M, Iguchi Y, Arakawa S, Fujimoto S, Okada Y, Ihara M, Takahashi S, Doijiri R, Sasaki M, Yakushiji Y, Hirano T, Toyoda K.

2026-02-27

10.1177/17474930261430910

Prediction Model to Optimize Long-Term Antithrombotic Therapy Using Covert Vascular Brain Injury and Clinical Features

Kaori Miwa, Kenta Tanaka, Masatoshi Koga, Kanta Tanaka, Yusuke Yakushiji et al. (22 authors)

Stroke2025-06-19

10.1161/strokeaha.125.050859

Increased Cerebral Small Vessel Disease Burden With Renal Dysfunction and Albuminuria in Patients Taking Antithrombotic Agents: The Bleeding With Antithrombotic Therapy 2

Kanta Tanaka, Kaori Miwa, Masahito Takagi, Makoto Sasaki, Yusuke Yakushiji et al. (18 authors)

Journal of the American Heart Association2022-03-0511 citations

10.1161/jaha.121.024749

Interventions

DRUGAny oral antithrombotics (antiplatelets or anticoagulants)

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

No

Inclusion criteria

* Patients with cerebrovascular or cardiovascular diseases who start or continue taking oral antithrombotics (antiplatelets and/or anticoagulants) to prevent vascular events * Patients who are able to receive MRI * Provision of written informed consent either directly or by a suitable surrogate

Exclusion criteria

* MRI contraindication * Any condition that in the opinion of the responsible physician or investigator that renders the patient unsuitable for the study

Design outcomes

Primary

Measure	Time frame
ISTH major bleeding	within 2 years

Secondary

Measure	Time frame
Clinically relevant non-major bleeding	within 2 years
Hemorrhagic event details	within 2 years
Ischemic events and those details	within 2 years

Countries

Japan

Outcome results

None listed